Under the terms of the agreement, Allergan is responsible for development and commercialization of optioned products, subject to Editas Medicine's option to co-develop and share equally in the profits and losses of two optioned products in the United States. Pharmaceuticals company Allergen and gene editing firm Editas Medicine have partnered to develop CRISPR genome editing medicine EDIT-101 , to treat eye disease Leber Congenital Amaurosis type 10 . The announcement follows a strategic alliance and collaboration agreement signed by the companies last year , which gave Allergen exclusive access to develop up to five Editas Medicine genome programmes , while giving Editas Medicine the option to co - develop and share the profit and loss of two products in the future . Leber Congenital Amaurosis is the leading cause of inherited childhood blindness .
Pharmaceuticals company Allergen and gene editing firm Editas Medicine have partnered to develop CRISPR genome editing medicine EDIT-101 , to treat eye disease Leber Congenital Amaurosis type 10 . The announcement follows a strategic alliance and collaboration agreement signed by the companies last year , which gave Allergen exclusive access to develop up to five Editas Medicine genome programmes , while giving Editas Medicine the option to co - develop and share the profit and loss of two products in the future . Leber Congenital Amaurosis is the leading cause of inherited childhood blindness .